Active Ingredient(s): Benralizumab
FDA Approved: * November 14, 2017
Pharm Company: * ASTRAZENECA AB
Category: Asthma

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Fasenra Overview

Benralizumab (INN, trade name Fasenra) is a monoclonal antibody which developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2] Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.[3][4] It was approved by the US FDA in November 2017 for the treatment of severe eosinophilic asthma.[5] References ^ Statement on an Nonproprietary Name adopted by the US...

Read more Fasenra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Benralizumab

Recent Fasenra Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 30mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Fasenra: (1 result)

Sorted by National Drug Code
  • 0310-1730 Fasenra 30 mg/ml Subcutaneous Injection, Solution by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Benralizumab or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 21 March 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.